Change over period
From:
To:
Zoom:
- 3M
- 6M
- YTD
- 1Y
- 3Y
- 5Y
- 10Y
- 15Y
- 20Y
- Max
Creative Medical Technology Holdings Inc
NASDAQ CELZ
Data sourced from
and
and
Download Data
Creative Medical Technology Holdings Inc Price to Earnings Ratio (P/E) on June 03, 2024: -5.33
Creative Medical Technology Holdings Inc Price to Earnings Ratio (P/E) is -5.33 on June 03, 2024, a -566.78% change year over year. The price to earnings ratio (P/E ratio) compares the market price per share of a company's stock to its earnings per share (EPS). It is calculated by dividing the market capitalization by the net income, divided by the number of outstanding shares. This ratio provides insights into the market's valuation of a company's earnings. A higher P/E ratio indicates that investors are willing to pay a higher price for each unit of earnings, suggesting higher market expectations for future earnings growth.
-
Creative Medical Technology Holdings Inc 52-week high Price to Earnings Ratio (P/E) is -0.63 on August 25, 2023, which is 88.11% above the current Price to Earnings Ratio (P/E).
-
Creative Medical Technology Holdings Inc 52-week low Price to Earnings Ratio (P/E) is -9.93 on July 25, 2023, which is -86.11% below the current Price to Earnings Ratio (P/E).
-
Creative Medical Technology Holdings Inc average Price to Earnings Ratio (P/E) for the last 52 weeks is -2.61.
Don’t Miss A Beat
Looking to stay ahead of the competition and stay informed? Receive your daily dose of market news, trends, and analysis to kickstart your day and stay up-to-date.
NASDAQ: CELZ
| CEO | Mr. Timothy Warbington |
| IPO Date | Nov. 6, 2015 |
| Location | United States |
| Headquarters | 211 East Osborn Road, Phoenix, AZ, United States, 85012 |
| Employees | 4 |
| Sector | Healthcare |
| Industry | Biotechnology |
Description
Creative Medical Technology Holdings, Inc., a commercial stage biotechnology company, focuses on novel biological therapeutics in the fields of immunotherapy, endocrinology, urology, neurology, and orthopedics in the United States. The company offers CaverStem to treat erectile dysfunction; FemCelz for the treatment of loss of genital sensitivity and dryness; and StemSpine, a regenerative stem cell procedure to treat degenerative disc disease. It also develops ImmCelz, an immunotherapy platform for multiple diseases; OvaStem for treatment of female infertility; CELZ-201 to treat Type 1 diabetes; AlloStemSpine for the treatment of chronic lower back pain; and Alova to treat infertility as a result of premature ovarian failure. In addition, the company develops products and services for various indications, including preventing the rejection of transplanted organs, kidney failure, liver failure, heart attack, and Parkinson's disease. Creative Medical Technology Holdings, Inc. is based in Phoenix, Arizona.
Key trends
StockViz Staff
September 19, 2024
Any question? Send us an email